dr. mettu on the potential of cpi-613 in metastatic pancreatic cancer
Published 5 years ago • 1K plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:25
dr. pardee on cpi-613 in hematologic malignancies
-
38:24
current and future directions in metastatic pancreatic cancer
-
1:48
dr. chung on sequencing chemotherapy regimens in metastatic pancreatic cancer
-
0:31
copy of dr. chung on sequencing chemotherapy regimens in metastatic pancreatic cancer
-
1:20
dr. powell on cpi-613, cytarabine, mitoxantrone combo for aml
-
1:47
dr. picozzi on the use of sm-88 in pancreatic cancer
-
3:31
cost effectiveness of frontline therapies for metastatic pancreatic cancer
-
5:23
metastatic pancreas cancer; sequencing therapies
-
13:38
treatment of metastatic pancreatic ductal cancer
-
7:14
metastatic pancreatic cancer: dosing strategies in the frontline setting
-
1:38
dr. pardee on cpi-613 for patients with r/r aml
-
2:35
dr. pardee discusses a phase i study of cpi-613 in advanced hematologic malignancies
-
3:17
what does dr. mettu's va do for his practice?
-
5:00
the potential for immunotherapy in pancreatic cancer
-
0:40
dr. powell on the next steps for cpi-613 in hematologic malignancies
-
0:52
dr. cohn on frontline therapies in metastatic pancreatic cancer
-
17:38
deciding the initial chemotherapy for patients with metastatic pancreatic cancer
-
4:07
dose escalation of cpi-613 with bendamustine for relapsed t cell nhl
-
0:16
dr. weinberg discusses the use of folfirinox in older patients with metastatic pancreatic cancer